|
|
Mckesson Corporation (NYSE: MCK) |
|
Price: $885.3200
$-8.07
-0.903%
|
| Day's High:
| $892.7849731445312
| Week Perf:
| -2.18 %
|
| Day's Low: |
$ 876.48 |
30 Day Perf: |
3.4 % |
| Volume (M): |
1,375,393 |
52 Wk High: |
$ 999.00 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$825.78 |
| Open: |
$882.83 |
52 Wk Low: |
$682.35 |
|
|
| Market Capitalization (Millions $) |
109,868 |
| Shares
Outstanding (Millions) |
124 |
| Employees |
51,000 |
| Revenues (TTM) (Millions $) |
403,430 |
| Net Income (TTM) (Millions $) |
5,099 |
| Cash Flow (TTM) (Millions $) |
-1,888 |
| Capital Exp. (TTM) (Millions $) |
745 |
Business Description
McKesson Corporation, is a Fortune 16 corporation providing supply, information
and care management products and services designed to reduce costs and improve
quality across the healthcare industry.
We conduct our business through three segments. Through our Pharmaceutical
Solutions segment, we are a leading distributor of ethical and proprietary drugs,
and health and beauty care products throughout North America. This segment also
manufactures and sells automated pharmaceutical dispensing systems for hospitals
and retail pharmacies, medical management and specialty pharmaceutical solutions
for biotech and pharmaceutical manufacturers, patient and payor services, consulting
and outsourcing services to pharmacies and distribution of first-aid products
in the United States. Our Medical-Surgical Solutions segment distributes medical-surgical
supplies and equipment, and provides logistics and related services within the
United States. Our Information Solutions segment delivers enterprise-wide patient
care, clinical, financial, supply chain, managed care and strategic management
software solutions, as well as outsourcing and other services, to healthcare
organizations throughout North America, the United Kingdom and other European
countries. The Company's strategy is to create strong, value-based relationships
with customers, enabling us to sell additional products and services to these
customers over time.
The U.S. Pharmaceutical Distribution business operates and serves over 30,000
locations through a network of 28 distribution centers, as well as a master
distribution center and a repackaging facility, serving all 50 states. We invest
in technology and other systems at all of our distribution centers to enhance
safety, reliability and the best product availability for our customers. For
example, in all of our distribution centers we use Acumax' Plus, a Smithsonian
award-winning technology, which integrates and tracks all internal functions,
such as receiving, put-away and order fulfillment. Acumax' Plus uses bar code
technology, wrist-mounted computer hardware, and radio frequency signals to
provide our customers with industry leading order quality and fulfillment at
up to 99.9% accuracy. Closed Loop DistributionSM, which integrates portable
Palm technology with Acumax' Plus to give customers complete ordering and inventory
control, and Supply Management OnlineSM, an Internet-based ordering, purchasing,
third-party reconciliation and account management system, help ensure that our
customers have the right products at the right time for their facilities and
patients.
Competition
In every area of healthcare distribution operations, our Pharmaceutical Solutions
and Medical-Surgical Solutions segments face strong competition, both in price
and service, from national, regional and local full-line, short-line and specialty
wholesalers, service merchandisers, self-warehousing chains, and manufacturers
engaged in direct distribution. In addition, these segments face competition
from various other service providers and from pharmaceutical and other healthcare
manufacturers (as well as other potential customers of the segments) which may
from time to time decide to develop, for their own internal needs, supply management
capabilities which are provided by the segments and other competing service
providers. Price, quality of service, and, in some cases, convenience to the
customer are generally the principal competitive elements in these segments.
Our Information Solutions segment experiences substantial competition from
many firms, including other computer services firms, consulting firms, shared
service vendors, certain hospitals and hospital groups, hardware vendors and
Internet-based companies with technology applicable to the healthcare industry.
Competition varies in size from small to large companies, in geographical coverage,
and in scope and breadth of products and services offered.
Company Address: 6555 State Hwy 161 Irving 75039 TX
Company Phone Number: 446-4800 Stock Exchange / Ticker: NYSE MCK
|
|
|
Customers Net Income grew by |
MCK's Customers Net Profit Margin grew to |
54.11 % |
3.9 %
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Fri, Sep 19 2025 8:39 AM UTC
In a decisive move to streamline operations and bolster its competitive positioning, McKesson Corporation (NYSE: MCK) recently unveiled a new organizational structure, set to take effect in the second quarter of fiscal year 2026. This significant shift reflects McKesson s commitment to enhancing strategic alignment and improving transparency within its reportable segments, a...
|
| Business Update
Published Wed, Apr 2 2025 3:10 PM UTC
In a significant move to bolster its position in the healthcare sector, McKesson Corporation has completed its acquisition of a controlling interest in PRISM Vision Holdings, LLC, a prominent provider of general ophthalmology and retina management services. This acquisition, valued at approximately $850 million, reflects McKesson s strategic intent to expand its footprint wi...
|
| Business Update
Published Sat, Jan 4 2025 6:21 PM UTC
McKesson s Strategic Shift: Divesting Some, Growing MoreOn December 30, 2024, McKesson Corporation, a leading name in healthcare services and information technology, finalized the sale of its Canadian subsidiaries, Rexall and Well.ca, to Birch Hill Equity Partners. This move, initially announced in September, signifies a strategic pivot for McKesson, allowing the company to...
|
| Business Update
Published Sat, Jan 4 2025 4:15 PM UTC
In a significant move to sharpen its operational focus and capital allocation, McKesson Corporation (NYSE: MCK) has completed the divestiture of its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, a prominent Canadian private equity firm. Announced in September 2024 and finalized on December 30, 2024, this strategic transaction is a pivotal part of ...
|
| Business Update
Published Sat, Jan 4 2025 2:45 PM UTC
McKesson s Bold Pivot: From Rexall to Oncology Is It the Right PrescriptionIn a strategic move set to reshape its focus, McKesson Corporation has formally divested its Canada-based Rexall and Well.ca businesses, sealing the deal with Birch Hill Equity Partners on December 30, 2024. This transaction marks another chapter in McKesson’s ongoing evolution within the ever-compe...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
38.31 $ |
| Revenues (TTM) |
3250.85 $
|
| Cash Flow (TTM) |
- |
| Cash |
32.03 $
|
| Book Value |
-
|
| Dividend (TTM) |
3.17 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
7,910,392 |
| Net
Income per Employee (TTM) |
99,980 |
| Receivable Turnover Ratio (TTM) |
14.33 |
| Inventory Turnover Ratio (TTM) |
15.18 |
| Asset Turnover Ratio (TTM) |
4.92 |
|
|
| Per Share |
|
| Earnings (TTM) |
38.31 $
|
| Revenues (TTM) |
3250.85 $ |
| Cash Flow (TTM) |
- |
| Cash |
32.03 $
|
| Book Value |
- |
| Dividend (TTM) |
3.17 $ |
|
|
| |
| North American Pharmaceutical |
|
83.2 % |
of total Revenue |
| Oncology Multispecialty |
|
12.26 % |
of total Revenue |
| Prescription Technology Solutions |
|
1.41 % |
of total Revenue |
| Medical-Surgical Solutions |
|
2.82 % |
of total Revenue |
| Other |
|
0.32 % |
of total Revenue |
| |
On February 6 2025 the Mckesson provided following guidance
nnMcKesson Corporation Increases Fiscal 2025 Full-Year Adjusted EPS Guidance Following Third Quarter Resultsnn
On February 6, 2025, McKesson Corporation (NYSE: MCK), based in Irving, Texas, proudly announced its financial results for the third quarter of fiscal 2025. In a notable development, the company has elevated its projected full-year adjusted earnings per share (EPS) guidance for the fiscal year, reflecting its strong performance and optimistic outlook. However, specific figures or ranges for the revised adjusted EPS guidance were not disclosed in the announcement.
Investors looking for detailed financial metrics may access the third quarter results directly through McKesson's Invest...
|
|
|